A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma

doi:10.1016/j.gendis.2023.02.019

UM > Faculty of Health Sciences

Residential College	false
Status	已發表Published
	A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma
	Wang, Weidong 1,5,6,7; Lv, Wang 1; Wang, Hui 1; Xu, Yang 3; Yan, Junrong 3; Shen, Han Ming4,5 ; Shan, Liqun 1,2; Hu, Jian 1
	2023-11-01
Source Publication	Genes and Diseases
ISSN	2352-4820
Volume	10 Issue:6 Pages:2241-2244
DOI	10.1016/j.gendis.2023.02.019
URL	View the original
Language	英語English
Scopus ID	2-s2.0-85162199986
Fulltext Access	View Full-Text via DOI View Full-Text via Scopus
Citation statistics
Document Type	Journal article
Collection	Faculty of Health Sciences
Affiliation	1.Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China 2.Department of Thoracic Surgery, The First People's Hospital of Wenling, Wenling, Zhejiang, 317599, China 3.Medical Department, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, 210000, China 4.Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore 5.Faculty of Health Sciences, University of Macau, Macau, SAR 519000, China 6.Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China 7.Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, China
First Author Affilication	Faculty of Health Sciences
Recommended Citation GB/T 7714	Wang, Weidong,Lv, Wang,Wang, Hui,et al. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma[J]. Genes and Diseases, 2023, 10(6), 2241-2244.
APA	Wang, Weidong., Lv, Wang., Wang, Hui., Xu, Yang., Yan, Junrong., Shen, Han Ming., Shan, Liqun., & Hu, Jian (2023). A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma. Genes and Diseases, 10(6), 2241-2244.
MLA	Wang, Weidong,et al."A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma".Genes and Diseases 10.6(2023):2241-2244.

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation No.
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh